Thank you for your interest in the Immunolight X-PACT 101 Study
The X-PACT 101 study is an experimental treatment to treat advanced solid cancerous tumors.
Please complete the following registration form to speak or email with one of our clinical trial experts.
By submitting this form I accept the Terms of Use and Privacy Policy.
Additional Resources
X-Ray Psoralen Activated Cancer Therapy (X-PACT)
This article summarizes the early development work of the X-PACT system. The effect on cell death in cancer cell lines, as well as the (in-vivo) effects on tumors in mouse studies are described.
Photo-Activated Psoralen Binds the ErbB2 Catalytic Kinase Domain, Blocking ErbB2 Signaling and Triggering Tumor Cell Apoptosis
The HER2 receptor is a validated oncology target, currently used with current FDA approved targeted therapies. Psoralen also binds to the HER2 receptor and induces cell death in cancers expressing HER2.
Extracorporeal Photopheresis—An Overview
This article summarizes decades of studies using psoralen, activated outside the body, in numerous diseases and disorders.
Extracorporeal photopheresis: Past, present, and future
This article further describes clinical trials and studies using psoralen in multiple diseases. Safety and effectiveness are described in both cancer and autoimmune disorders.
Psoralen photobiology and photochemotherapy: 50 years of science and medicine
This 1998 article describes the 50 year anniversary of using psoralen, in the oral formulation, to treat refractory psoriasis.